Nefazodone treatment of adolescent depression

An open-label study of response and biochemistry

Paul J. Goodnick, Cecilia A. Jorge, Thomas Hunter, Adarsh Kumar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: The purpose of this study was to find whether nefazodone, effective in adult depression, might be similarly improve symptoms of adolescent depression. Secondary purpose was to relate platelet serotonin content to response, and to find if nefazodone's effect on platelet content was similar to that of the SSRIs. Method: 10 adolescents meeting DSMIV criteria for major depression received up to 400 mg of nefazodone for an eight week period. Response was assessed at baseline, 1, 2, 4, and 8 weeks by BDI and HDRS; platelet serotonin (5HT) content was obtained at baseline and final visit (for two dropouts, this was done at last visit, i.e., week 4). Results: In LOCF analysis, significant improvement was found in both HDRS (20.9 to 8.9, p = .01) and BDI (24.6 to 10.2, p = .01). Eight of nine patients with available data showed increases in platelet 5HT content (.02). In seven patients of eight completers with available data, there was a nonsignificant trend for patients with platelet 5HT baseline greater than 30 ng/108 platelets to show a greater change in HDRS than those with a baseline of less than 30 ng/108 platelets (p = .07). Conclusions: Further double- blind study of nefazodone in adolescent depression is indicated; nefazodone appears to increase platelet 5HT content.

Original languageEnglish
Pages (from-to)97-100
Number of pages4
JournalAnnals of Clinical Psychiatry
Volume12
Issue number2
DOIs
StatePublished - Aug 2 2000

Fingerprint

Biochemistry
Blood Platelets
Therapeutics
Serotonin
nefazodone
Double-Blind Method

Keywords

  • Adolescent
  • Antidepressants
  • Depression
  • Nefazodone
  • Serotonin

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Nefazodone treatment of adolescent depression : An open-label study of response and biochemistry. / Goodnick, Paul J.; Jorge, Cecilia A.; Hunter, Thomas; Kumar, Adarsh.

In: Annals of Clinical Psychiatry, Vol. 12, No. 2, 02.08.2000, p. 97-100.

Research output: Contribution to journalArticle

Goodnick, Paul J. ; Jorge, Cecilia A. ; Hunter, Thomas ; Kumar, Adarsh. / Nefazodone treatment of adolescent depression : An open-label study of response and biochemistry. In: Annals of Clinical Psychiatry. 2000 ; Vol. 12, No. 2. pp. 97-100.
@article{8d2caaca079a46008531ed62b48c4083,
title = "Nefazodone treatment of adolescent depression: An open-label study of response and biochemistry",
abstract = "Objective: The purpose of this study was to find whether nefazodone, effective in adult depression, might be similarly improve symptoms of adolescent depression. Secondary purpose was to relate platelet serotonin content to response, and to find if nefazodone's effect on platelet content was similar to that of the SSRIs. Method: 10 adolescents meeting DSMIV criteria for major depression received up to 400 mg of nefazodone for an eight week period. Response was assessed at baseline, 1, 2, 4, and 8 weeks by BDI and HDRS; platelet serotonin (5HT) content was obtained at baseline and final visit (for two dropouts, this was done at last visit, i.e., week 4). Results: In LOCF analysis, significant improvement was found in both HDRS (20.9 to 8.9, p = .01) and BDI (24.6 to 10.2, p = .01). Eight of nine patients with available data showed increases in platelet 5HT content (.02). In seven patients of eight completers with available data, there was a nonsignificant trend for patients with platelet 5HT baseline greater than 30 ng/108 platelets to show a greater change in HDRS than those with a baseline of less than 30 ng/108 platelets (p = .07). Conclusions: Further double- blind study of nefazodone in adolescent depression is indicated; nefazodone appears to increase platelet 5HT content.",
keywords = "Adolescent, Antidepressants, Depression, Nefazodone, Serotonin",
author = "Goodnick, {Paul J.} and Jorge, {Cecilia A.} and Thomas Hunter and Adarsh Kumar",
year = "2000",
month = "8",
day = "2",
doi = "10.1023/A:1009024214337",
language = "English",
volume = "12",
pages = "97--100",
journal = "Annals of Clinical Psychiatry",
issn = "1040-1237",
publisher = "Dowden Health Media,Inc",
number = "2",

}

TY - JOUR

T1 - Nefazodone treatment of adolescent depression

T2 - An open-label study of response and biochemistry

AU - Goodnick, Paul J.

AU - Jorge, Cecilia A.

AU - Hunter, Thomas

AU - Kumar, Adarsh

PY - 2000/8/2

Y1 - 2000/8/2

N2 - Objective: The purpose of this study was to find whether nefazodone, effective in adult depression, might be similarly improve symptoms of adolescent depression. Secondary purpose was to relate platelet serotonin content to response, and to find if nefazodone's effect on platelet content was similar to that of the SSRIs. Method: 10 adolescents meeting DSMIV criteria for major depression received up to 400 mg of nefazodone for an eight week period. Response was assessed at baseline, 1, 2, 4, and 8 weeks by BDI and HDRS; platelet serotonin (5HT) content was obtained at baseline and final visit (for two dropouts, this was done at last visit, i.e., week 4). Results: In LOCF analysis, significant improvement was found in both HDRS (20.9 to 8.9, p = .01) and BDI (24.6 to 10.2, p = .01). Eight of nine patients with available data showed increases in platelet 5HT content (.02). In seven patients of eight completers with available data, there was a nonsignificant trend for patients with platelet 5HT baseline greater than 30 ng/108 platelets to show a greater change in HDRS than those with a baseline of less than 30 ng/108 platelets (p = .07). Conclusions: Further double- blind study of nefazodone in adolescent depression is indicated; nefazodone appears to increase platelet 5HT content.

AB - Objective: The purpose of this study was to find whether nefazodone, effective in adult depression, might be similarly improve symptoms of adolescent depression. Secondary purpose was to relate platelet serotonin content to response, and to find if nefazodone's effect on platelet content was similar to that of the SSRIs. Method: 10 adolescents meeting DSMIV criteria for major depression received up to 400 mg of nefazodone for an eight week period. Response was assessed at baseline, 1, 2, 4, and 8 weeks by BDI and HDRS; platelet serotonin (5HT) content was obtained at baseline and final visit (for two dropouts, this was done at last visit, i.e., week 4). Results: In LOCF analysis, significant improvement was found in both HDRS (20.9 to 8.9, p = .01) and BDI (24.6 to 10.2, p = .01). Eight of nine patients with available data showed increases in platelet 5HT content (.02). In seven patients of eight completers with available data, there was a nonsignificant trend for patients with platelet 5HT baseline greater than 30 ng/108 platelets to show a greater change in HDRS than those with a baseline of less than 30 ng/108 platelets (p = .07). Conclusions: Further double- blind study of nefazodone in adolescent depression is indicated; nefazodone appears to increase platelet 5HT content.

KW - Adolescent

KW - Antidepressants

KW - Depression

KW - Nefazodone

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=0033926812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033926812&partnerID=8YFLogxK

U2 - 10.1023/A:1009024214337

DO - 10.1023/A:1009024214337

M3 - Article

VL - 12

SP - 97

EP - 100

JO - Annals of Clinical Psychiatry

JF - Annals of Clinical Psychiatry

SN - 1040-1237

IS - 2

ER -